Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market Pipeline Review, H2 2016

Friday, November 11, 2016 2:57
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Latest Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review, H2 2016, provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics.

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer therapeutics industry report provides comprehensive information on the therapeutics under development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and features dormant and discontinued projects.
 

Browse more detail information about Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer market report at: http://www.absolutereports.com/hormone-refractory-castration-resistant-androgen-independent-prostate-cancer-pipeline-review-h2-2016-10405154

 

Prostate cancer no longer responds to hormone therapy and growth of the cancer continues, it is called hormone resistant or hormone refractory prostate cancer. This occurs if cancer cells do not need testosterone for growth. Symptoms include fatigue, blood in the urine, pain in the hips, back (spine), chest (ribs), or other areas from cancer spread to bones, loss of appetite, or weight loss. Predisposing factors include age, smoking and family history. Treatment includes chemotherapy and radiotherapy.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key players in Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline Review, H2 2016:
 

  • Advaxis, Inc.
  • Aeterna Zentaris Inc.
  • Ambrx, Inc.
  • Amgen Inc.
  • AnGes MG, Inc.
  • Aphios Corporation
  • ARMO Biosciences, Inc.
  • Armour Therapeutics Inc.
  • Arno Therapeutics, Inc.
  • ArQule, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Arvinas, Inc.
  • Asana BioSciences, LLC
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • ATLAB Pharma SAS
  • Bavarian Nordic A/S

And More

Get a PDF Sample of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Market Research Report at: http://www.absolutereports.com/enquiry/request-sample/10405154

Key Topics Covered:
1.Introduction
2.Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview
3.Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Development
4.Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Overview
5.Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Comparative Analysis
6.Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Therapeutics under Development by Companies
7.Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Therapeutics under Investigation by Universities/Institutes
8.Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Products Glance
9.Late Stage Products
10.Clinical Stage Products
11.Early Stage Products
12.Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Products under Development by Companies
13.Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Products under Investigation by Universities/Institutes
14.Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Companies Involved in Therapeutics Development
15.Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Drug Profiles
16.Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Dormant Projects
17.Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Discontinued Products
18.Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Featured News & Press Releases
And Continue…

Get Discount on Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Market Research Report at: http://www.absolutereports.com/enquiry/request-discount/10405154

This research study help to:
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

About Absolute Report:

Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.

Contact–

Mr. Ameya Pingaley

Absolute Reports

+1-408 520 9750

Email – sales@absolutereports.com

www.absolutereports.com

 

 

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.